CE / CME
In this Interactive Case Challenge, make clinical decisions to optimize personalized treatment for a patient with medullary thyroid cancer.
Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit
Nurses: 0.25 Nursing contact hour
Pharmacists: 0.25 contact hour (0.025 CEUs)
Physicians: maximum of 0.25 AMA PRA Category 1 Credit™
ABIM MOC: maximum of 0.25 Medical Knowledge MOC point
Released: September 17, 2024
Expiration: September 16, 2025
Share
Joseph H. Friedman, MD
Professor and Chief
Division of Movement Disorders
Department of Neurology
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Saad A Khan, MD
Leader Endocrine Cancer Research Group
Associate Professor of Medicine (Oncology)
Stanford University
Stanford Cancer Institute
Stanford, California
Diane K. Newman, DNP, ANP-BC, FAAN
Adjunct Professor of Urology in Surgery
Research Investigation Senior
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire
Steven Christopher Smith, MD, PhD
Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia
Provided by Clinical Care Options, LLC, in partnership with Q Synthesis and the Association for Molecular Pathology
This activity is supported by an educational grant from Lilly.
Lilly
AMP
Q Synthesis LLC
Oncologists, pathologists, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who manage patients with cancer within 3 community and academic cancer centers.
The overall initiative aim by the conclusion of this project is to improve clinical outcomes in patients with advanced solid tumors harboring actionable biomarkers among participating clinic sites.
Upon completion of this activity, participants should be able to:
Accurately interpret molecular pathology results to select appropriate targeted therapies for patients with advanced solid tumors prior to initiating therapy
Communicate the rationale for molecular testing to patients and its critical value in determining their treatment plans
Select and sequence individualized genomic alteration–directed targeted therapy for patients with solid tumors based on current evidence, guidelines, expert recommendations, and tumor molecular profile
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Saad A Khan, MD
Leader Endocrine Cancer Research Group
Associate Professor of Medicine (Oncology)
Stanford University
Stanford Cancer Institute
Stanford, California
Saad A. Khan, MD: consultant/advisor/speaker: EMD Serono, Foundation Medicine, Genmab: data and safety monitoring committee: Kineta.
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire
Laura J. Tafe, MD, has no relevant financial relationships to disclose.
Joseph H. Friedman, MD
Professor and Chief
Division of Movement Disorders
Department of Neurology
Warren Alpert Medical School of Brown University
Providence, Rhode Island
The planners and content peer reviewers from Clinical Care Options, LLC, Q Synthesis, and the Association for Molecular Pathology do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, RNP, AOCNP, as noted below.
Kristi K. Orbaugh, MSN, RNP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, Pfizer, Regeneron, SOBI.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 17, 2024, through September 16, 2025:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), Q Synthesis, and the Association for Molecular Pathology. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-24-239-H01-P
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 16, 2025. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
CME for MIPS
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.
CME Passport
The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.